XTL Biopharmaceuticals
XTLB
6 hedge funds and large institutions have $2.13M invested in XTL Biopharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
20% more funds holding
Funds holding: 5 → 6 (+1)
7% more capital invested
Capital invested by funds: $2M → $2.13M (+$136K)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$51.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$60K |
| 2 |
SW
SteelPeak Wealth
Woodland Hills,
California
|
-$47K |
| 3 |
Morgan Stanley
New York
|
-$9.63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $871K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $871K | – | – | – |
|
|
3
Morgan Stanley
New York
| $226K | -$9.63K | -598 | -4% |
|
|
4
Renaissance Technologies
New York
| $98K | -$60K | -3,727 | -40% |
|
|
5
Citadel Advisors
Miami,
Florida
| $56K | +$51.6K | +3,200 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $13K | +$11.7K | +725 | New |
|
|
SW
7
SteelPeak Wealth
Woodland Hills,
California
| – | -$47K | -2,918 | Closed |
|
XTLB Hedge Fund Activity: Q3 2021 in Review
6 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2021, worth a combined $2.13M — up 6.8% from $2M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XTLB positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $51.6K. The largest seller was Renaissance Technologies, cutting an estimated $60K.
- 6 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2021, up from 5 in Q2 2021.
- Funds reported $2.13M of XTL Biopharmaceuticals stock for Q3 2021, up 6.8% quarter-over-quarter.
- 2 funds opened new XTL Biopharmaceuticals positions in Q3 2021 and 1 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q3 2021 was Citadel Advisors, an estimated $51.6K added.
- The largest XTL Biopharmaceuticals seller in Q3 2021 was Renaissance Technologies, an estimated $60K sold.
Based on aggregated 13F filings for Q3 2021.